Pasithea Therapeutics Corp is a biotechnology company... Show more
Pasithea Therapeutics Corp. is a clinical-stage biotechnology company headquartered in Miami Beach, Florida, focused on discovering and developing treatments for RASopathies, MAPK pathway-driven tumors, and other diseases, including central nervous system (CNS) disorders. Its lead candidate, PAS-004, is a next-generation macrocyclic oral MEK inhibitor designed for long-term, once-daily chronic dosing. The company is advancing PAS-004 in a Phase 1 trial in advanced solid tumors and a Phase 1/1b trial in adult patients with NF1-associated plexiform neurofibromas (PN), and now a planned Phase 2 program in NF1-associated cutaneous neurofibromas (cNF). Pasithea has also secured FDA Fast Track and Rare Pediatric Disease designations for PAS-004 in NF1-PN, as well as Orphan Drug Designation for ALS. Investors follow the stock primarily for clinical data readouts and regulatory milestones tied to PAS-004.
Over the last 30 days, KTTA advanced approximately +31%, rising from a close near $0.44 in early October to roughly $0.58 in early November. The move was not gradual: the shares were drifting in the low-$0.40 range for most of October before jumping sharply on November 3, when daily volume surged to roughly 10 million shares versus a typical range of roughly 50,000 to 400,000 shares.
The broader multi-month trend tells a more volatile story. From a close of about $0.58 in early September, the stock declined steadily through October, reaching a trough near $0.37 in late October. The early-November catalyst-driven rebound brought the shares back to approximately their early-September level, meaning the stock is roughly flat over the full quarter despite a significant drawdown and recovery along the way. This volatility reflects the binary, news-driven nature of a small-cap clinical-stage biotech.
The dominant driver of the 30-day move was the FDA's clearance of Pasithea's IND application for PAS-004 in NF1-associated cutaneous neurofibromas. Announced on November 3, the clearance allows a randomized, placebo-controlled Phase 2 trial in the United States for a condition affecting more than 95% of people with NF1 and for which no FDA-approved systemic therapies exist. The company has previously noted it estimates more than 80,000 people in the U.S. have moderate-to-severe NF1-associated cNF. This expansion of the PAS-004 franchise beyond plexiform neurofibromas broadened the program's addressable market and triggered a sharp re-rating, with unusually heavy trading volume.
Supporting the move, Pasithea also scheduled a virtual key opinion leader event on NF1 treatment for November 4, featuring academic experts from the University of Alabama at Birmingham and Stanford, which reinforced investor attention on the NF1 franchise. In addition, the company had previously announced it would present initial Phase 1/1b data in adult NF1 patients at the European Neurofibromatosis Conference in Vienna, keeping a near-term data catalyst in view.
Over the most recent quarter, KTTA traded lower for much of the period before the November rebound. Following a $60 million public offering that closed in early December 2025 — which issued 80 million shares at $0.75 each to healthcare-dedicated investors including Vivo Capital, Janus Henderson, Coastlands Capital, Columbia Threadneedle, Adage Capital Partners, and Squadron Capital — the stock carried a substantial dilution overhang into 2026 and drifted downward through the spring and summer despite a stream of positive pipeline updates. Those updates included positive interim Phase 1 advanced-cancer data in late June, clinical protocol amendments, an ESMO Congress 2026 poster presentation in October, and multiple regulatory designations. The October low reflected broad pressure on small-cap biotech names, while the early-November IND clearance re-established positive momentum and returned the shares to their early-September level.
Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots from a broader platform that operates hundreds of automated strategies across thousands of tickers. Only the top-performing and most relevant bots are featured in this section, with each bot differing in trading strategy, timeframe, and performance metrics. The page is designed to help traders compare algorithmic approaches and identify strategies that align with their objectives. For investors looking to complement fundamental analysis of names like KTTA with systematic, data-driven signals, the curated list offers a practical starting point.
Several verified catalysts are on the near-term horizon. Pasithea is scheduled to present initial Phase 1/1b Part A clinical data in adult NF1 patients at the European Neurofibromatosis Conference in Vienna from November 12–14, representing the first public disclosure of that trial's data. The company's third-quarter earnings report is also anticipated in mid-November, with analysts estimating a loss of approximately $0.21 per share. On the regulatory front, the newly cleared cNF Phase 2 trial's initiation and enrollment progress will be closely watched, alongside continued dose escalation in the advanced-cancer study. Analyst coverage remains constructive, with H.C. Wainwright reiterating a Buy rating and a $3.00 price target and a consensus rating of Moderate Buy. As a pre-revenue clinical-stage company, KTTA remains sensitive to clinical data, regulatory outcomes, financing decisions, and broader small-cap biotech sentiment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 10-day RSI Indicator for KTTA moved out of overbought territory on November 09, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 instances where the indicator moved out of the overbought zone. In 17 of the 17 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KTTA as a result. In 84 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for KTTA turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 44 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KTTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KTTA broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KTTA entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 69 cases where KTTA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
KTTA moved above its 50-day moving average on November 18, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KTTA crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.388) is normal, around the industry mean (3.596). P/E Ratio (-0.429) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. KTTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KTTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology